Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
LA JOLLA, Calif.--(BUSINESS WIRE)-- #ANRE--Arialys' Nature Communications Paper Supports ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDAR Autoimmune Neuropsychiatric Disease